Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1985 5
1986 3
1987 4
1988 13
1989 14
1990 13
1991 11
1992 25
1993 18
1994 14
1995 27
1996 21
1997 14
1998 16
1999 15
2000 15
2001 26
2002 8
2003 28
2004 22
2005 23
2006 28
2007 22
2008 23
2009 26
2010 36
2011 47
2012 47
2013 60
2014 44
2015 59
2016 79
2017 47
2018 65
2019 62
2020 68
2021 78
2022 68
2023 57
2024 41

Text availability

Article attribute

Article type

Publication date

Search Results

1,100 results

Results by year

Filters applied: . Clear all
Page 1
Crohn's disease.
Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Torres J, et al. Among authors: colombel jf. Lancet. 2017 Apr 29;389(10080):1741-1755. doi: 10.1016/S0140-6736(16)31711-1. Epub 2016 Dec 1. Lancet. 2017. PMID: 27914655 Review.
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD.
Turner D, Ricciuto A, Lewis A, D'Amico F, Dhaliwal J, Griffiths AM, Bettenworth D, Sandborn WJ, Sands BE, Reinisch W, Schölmerich J, Bemelman W, Danese S, Mary JY, Rubin D, Colombel JF, Peyrin-Biroulet L, Dotan I, Abreu MT, Dignass A; International Organization for the Study of IBD. Turner D, et al. Among authors: colombel jf. Gastroenterology. 2021 Apr;160(5):1570-1583. doi: 10.1053/j.gastro.2020.12.031. Epub 2021 Feb 19. Gastroenterology. 2021. PMID: 33359090
Upadacitinib Induction and Maintenance Therapy for Crohn's Disease.
Loftus EV Jr, Panés J, Lacerda AP, Peyrin-Biroulet L, D'Haens G, Panaccione R, Reinisch W, Louis E, Chen M, Nakase H, Begun J, Boland BS, Phillips C, Mohamed MF, Liu J, Geng Z, Feng T, Dubcenco E, Colombel JF. Loftus EV Jr, et al. Among authors: colombel jf. N Engl J Med. 2023 May 25;388(21):1966-1980. doi: 10.1056/NEJMoa2212728. N Engl J Med. 2023. PMID: 37224198 Free article. Clinical Trial.
Multiomics to elucidate inflammatory bowel disease risk factors and pathways.
Agrawal M, Allin KH, Petralia F, Colombel JF, Jess T. Agrawal M, et al. Among authors: colombel jf. Nat Rev Gastroenterol Hepatol. 2022 Jun;19(6):399-409. doi: 10.1038/s41575-022-00593-y. Epub 2022 Mar 17. Nat Rev Gastroenterol Hepatol. 2022. PMID: 35301463 Free PMC article. Review.
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.
Sands BE, Peyrin-Biroulet L, Loftus EV Jr, Danese S, Colombel JF, Törüner M, Jonaitis L, Abhyankar B, Chen J, Rogers R, Lirio RA, Bornstein JD, Schreiber S; VARSITY Study Group. Sands BE, et al. Among authors: colombel jf. N Engl J Med. 2019 Sep 26;381(13):1215-1226. doi: 10.1056/NEJMoa1905725. N Engl J Med. 2019. PMID: 31553834 Clinical Trial.
Mild Crohn's Disease: Definition and Management.
Claytor J, Kumar P, Ananthakrishnan AN, Colombel JF, Agrawal M, Ungaro RC. Claytor J, et al. Among authors: colombel jf. Curr Gastroenterol Rep. 2023 Mar;25(3):45-51. doi: 10.1007/s11894-023-00863-y. Epub 2023 Feb 8. Curr Gastroenterol Rep. 2023. PMID: 36753033 Review.
Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis.
Sandborn WJ, Feagan BG, D'Haens G, Wolf DC, Jovanovic I, Hanauer SB, Ghosh S, Petersen A, Hua SY, Lee JH, Charles L, Chitkara D, Usiskin K, Colombel JF, Laine L, Danese S; True North Study Group. Sandborn WJ, et al. Among authors: colombel jf. N Engl J Med. 2021 Sep 30;385(14):1280-1291. doi: 10.1056/NEJMoa2033617. N Engl J Med. 2021. PMID: 34587385 Clinical Trial.
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials.
D'Haens G, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, Dubinsky M, Feagan BG, Hisamatsu T, Lim A, Lindsay JO, Loftus EV Jr, Panés J, Peyrin-Biroulet L, Ran Z, Rubin DT, Sandborn WJ, Schreiber S, Neimark E, Song A, Kligys K, Pang Y, Pivorunas V, Berg S, Duan WR, Huang B, Kalabic J, Liao X, Robinson A, Wallace K, Ferrante M. D'Haens G, et al. Among authors: colombel jf. Lancet. 2022 May 28;399(10340):2015-2030. doi: 10.1016/S0140-6736(22)00467-6. Lancet. 2022. PMID: 35644154 Clinical Trial.
Biopsy and blood-based molecular biomarker of inflammation in IBD.
Argmann C, Hou R, Ungaro RC, Irizar H, Al-Taie Z, Huang R, Kosoy R, Venkat S, Song WM, Di'Narzo AF, Losic B, Hao K, Peters L, Comella PH, Wei G, Atreja A, Mahajan M, Iuga A, Desai PT, Branigan P, Stojmirovic A, Perrigoue J, Brodmerkel C, Curran M, Friedman JR, Hart A, Lamousé-Smith E, Wehkamp J, Mehandru S, Schadt EE, Sands BE, Dubinsky MC, Colombel JF, Kasarskis A, Suárez-Fariñas M. Argmann C, et al. Among authors: colombel jf. Gut. 2023 Jul;72(7):1271-1287. doi: 10.1136/gutjnl-2021-326451. Epub 2022 Sep 15. Gut. 2023. PMID: 36109152 Free PMC article.
1,100 results